fibrinolytic therapy
DESCRIPTION
FIBRINOLYTIC THERAPY. (Thrombolytic Therapy). OBJECTIVES. Identify the indications for use in AMI Identify the indications for use in acute non-hemorrhagic stroke Have knowledge of patient selection criteria Have an enlarged scope of knowledge with regard to fibrinolytics. INTRODUCTION. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/1.jpg)
FIBRINOLYTIC THERAPY
(Thrombolytic Therapy)
![Page 2: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/2.jpg)
OBJECTIVES
Identify the indications for use in AMI Identify the indications for use in
acute non-hemorrhagic stroke Have knowledge of patient selection
criteria Have an enlarged scope of knowledge
with regard to fibrinolytics
![Page 3: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/3.jpg)
INTRODUCTION
The goal of fibrinolytic therapy is to dissolve occlusive clots.
Thrombus occlusion leads to cessation of blood flow to the affected area leading to oxygen deprivation and tissue damage distal to the occlusion, leading to irreversible damage and possibly death.
![Page 4: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/4.jpg)
THROMBOGENESIS
Traumatized tissue Activation of coagulation cascade
Thrombin Production of fibrinogen Fibrin
Fibrin strands cross-link and trap red blood cells and platelets
Clot is formed
![Page 5: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/5.jpg)
FIBRINOLYSIS
Plasminogen activation Convert to Plasmin
Fibrin clot
![Page 6: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/6.jpg)
Fibrinolytic therapy in AMI
Clot can be dissolved
Institute early Limits infarct size Preserve
myocardial function Decrease mortality
and morbidity
![Page 7: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/7.jpg)
Patient selection criteria
Continuous CP lasting at least 30 min Symptom onset within 12 hours ST elevation in 2 contiguous leads CP unrelieved by NTG or nifedipine No absolute contraindications present Initiation of therapy can be prompt
![Page 8: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/8.jpg)
Absolute Contraindications
Any hx of intracranial hemorrhage Known intracranial neoplasm or AV
malformation Suspected aortic dissection Active bleeding
![Page 9: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/9.jpg)
General pre-fibrinolytic procedures
Obtain orders Explain to pt and
family Obtain informed
consent Baseline labs and
diagnostic tests At least 2 IV lines
Gather equipment:1. Phillips monitor2. Zoll at bedside3. Ambu bag ready4. Suction 5. Crash cart nearby6. Infusion pumps (3)
![Page 10: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/10.jpg)
![Page 11: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/11.jpg)
Tenecteplase (TNK)
Binds to fibrin and converts plasminogen to plasmin
Decreases circulating fibrinogen and plasminogen
![Page 12: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/12.jpg)
TNK
Weight based One dose Reconstitute TNK vile with 10cc
sterile H2O Gently swirl Give single bolus over 5 seconds Maximum dose 50MG
![Page 13: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/13.jpg)
TNK-Adverse reactions
Bleeding-internal or superficial
Reperfusion arrhythmias
Allergic rxn Coronary artery
re-occlusion
![Page 14: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/14.jpg)
Surface Bleeding
Establish all peripheral IV sites prior to fibrinolytic infusion
Avoid IM injections Monitor all venous and arterial
sites frequently Apply direct pressure to all
bleeding for a minimum of 30 min. or homeostasis achieved
![Page 15: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/15.jpg)
Coronary Artery Reperfusion
Normalization of the ST segment Resolution of the CP or ischemic
symptoms Reperfusion arrhythmias May not have any of the above
![Page 16: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/16.jpg)
Reperfusion Arrhythmias
Bradycardia
V- tach
Heart Blocks
![Page 17: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/17.jpg)
Eftifibatide (Integrilin)
A cyclic amino acid that binds to the platelet receptor glycoprotein GP IIb/IIIa of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen
Used in combination with heparin and ASA
![Page 18: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/18.jpg)
Integrilin
Weight based dosing, use insert chart
Initial bolus 180mcg/kg-single dose over 1-2 minutes
Infusion of 2mcg/kg/min. Glass 100 ml bottle. Need vented spike
Refrigerated Option of low dose renal dose
![Page 19: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/19.jpg)
Compatible With…
Alteplase Atropine Dobutamine
Heparin Lidocaine Metoprolol
Morphine Nitroglycerine
Verapamil
![Page 20: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/20.jpg)
Tissue Plasminogen Activator (Activase,t-PA)
Activase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin
Then initiates local fibrinolysis
Give within 3 hours of stroke s/s
![Page 21: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/21.jpg)
Indications for MI
Lysis of thrombi obstruction in the coronary arteries
Reduction of infarct size Improvement of ventricular
function Reduction of incidence of CHF
![Page 22: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/22.jpg)
Indications for stroke
Improve neurologic recovery Reduce incidence of disability
![Page 23: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/23.jpg)
t-PA Reconstitution
Open Activase powder and 100cc sterile H2o
Using piercing pin, push into Activase vial
Attach sterile water bottle to top Allow the entire contents of water
to flow down , invert gently
![Page 24: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/24.jpg)
t-PA Administration
Use a separate IV line, use IV pump Dosing different for stroke, pulmonary
emboli, CVAD occlusions, and AMI STROKE-0.9 mg/kg IV over one hour.
With 10% of the dose given IV push over one minute
Max dose is 90mg
![Page 25: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/25.jpg)
T-PA for MI
100 mg over 90 min.
Bolus 15mg over 2 min.
Then 50 mg over 30 min.
Infuse last 35 mg over 60 min.
![Page 26: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/26.jpg)
Heparin
Combines with other factors in the blood to inhibit the conversion of prothrombin to thrombin, and fibrinogen to fibrin
Adhesiveness of platelets is reduced
Well-established clots are not dissolved, growth is prevented and newer clots may be resolved
![Page 27: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/27.jpg)
Heparin
Compatible with NTG and morphine at Y-site
Antidote – Protamine
sulfate
![Page 28: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/28.jpg)
Nitroglycerin
A vascular smooth –muscle relaxant and vasodilator.
Affects arterial and venous beds
Reduces myocardial O2 consumption, preload and afterload
![Page 29: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/29.jpg)
Nitroglycerin Administration
Glass bottle, vented spike
IV pump required. Given as mcg/min Usually 10-30mcg,
titrate to pain Lasts only 3-5
minutes
Compatible at Y-site with morphine and t-PA,heparin
Side effects: abdominal pain, allergic rxn, dizzy, HA, low BP
![Page 30: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/30.jpg)
Metoprolol (Lopressor)
Cardioselective adrenergic blocking agent
Reduces incidence of recurrent MI Reduces size of the infarct and the
incidence of fatal arrhythmias Lasts 4 hours Contraindicated in HR < 45
![Page 31: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/31.jpg)
Lopressor Administration
Five milligrams at five minute intervals to a total dose of 15 mg
Monitor rhythm, BP and HR between all doses
Hold for SBP less than 100 Compatible at Y-site with morphine
![Page 32: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/32.jpg)
Concurrent Drugs
Aspirin
NTG sublingual
Lidocaine
Nifedipine
![Page 33: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/33.jpg)
Door to drug time is
30 minutes
![Page 34: FIBRINOLYTIC THERAPY](https://reader030.vdocuments.site/reader030/viewer/2022032612/5681319e550346895d980df0/html5/thumbnails/34.jpg)